(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number
WO 2005/047326 A2

(51) International Patent Classification[7]: C07K 16/00

(21) International Application Number:
PCT/US2004/037518

(22) International Filing Date:
9 November 2004 (09.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/518,999 10 November 2003 (10.11.2003) US

(71) Applicant *(for all designated States except US)*: **SCHERING CORPORATION** [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **PRESTA, Leonard, G.** [US/US]; 1900 Gough Street, No. 206, San Francsico, California 94109 (US).


(74) Agent: **TRIOLO, Thomas, A.**; Schering-Plough Corporation, 2000 Galloping Hill Road, Mailstop K-6-1 1990, Kenilworth, New Jersey 07033 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: INTERLEUKIN-10 ANTIBODIES



12G8 VL sequence ↑ = Affects CDR (Chothia et al.) ^ = Affects CDR Δ = Interface

VLK I

```
            10        20        30            40        50        60        70        80        90
12G8   DIQMTQSPSLLSASVGDRVTLNC KTSQNIF----ENLA  WYQQKLREPPKLLIF NASPLQA GIPSRFSGSGSGTDFTLTITSLQPEDVATYFC HQYYSGY
47      4 3                   4       4    2 2     2 234       2       3 4     4                  4
47     1 1 11111 1111111111  1              1 1 1     1           1 111 1 111111 1111 111111 111 1
Z-012  DIQMTQSPSSLSASVGDRVTITC RASQSIS----SYLN  WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSYSTP
       ↑ ^                   ↑  ↑       ↑Δ    Δ Δ    ΔΔ Δ^↑Δ      Δ   ^   ^ ↑      ↑              Δ  Δ↑Δ  Δ↑
```

VLK II

```
            10        20        30            40        50        60        70        80        90
12G8   DIQMTQSPSLLSASVGDRVTLNC KTSQNIF------ENLA WYQQKLREPPKLLIF NASPLQA GIPSRFSGSGSGTDFTLTITSLQPEDVATYFC HQYYSGY
40      4 3                            4   2 2     2 234             2 4     4                  4
28     1   1111  1    1      1              1   1                 1 1 1 1 111111 11 1     111  1 1
Z-A19  DIVMTQSPLSLPVTPGEPASISC RSSQSLLHS-NGYNYLD WYLQKPGQSPQLLIY LGSNRAS GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC MQALQTP
       ↑ ^                   ↑  ↑       ↑Δ  Δ Δ    ΔΔ Δ^↑Δ      Δ   ^   ^ ↑      ↑              Δ  Δ↑Δ  Δ↑
```

VLK III

```
            10        20        30            40        50        60        70        80        90
12G8   DIQMTQSPSLLSASVGDRVTLNC KTSQNIF-ENLA     WYQQKLREPPKLLIF NASPLQA GIPSRFSGSGSGTDFTLTITSLQPEDVATYFC HQYYSGY
45      4                            42      2 2     2 234          3   3 4     4                  42
36         1111  11 1 1 1 11 1              1 1 1                 1 1 1 1 111111 1111  1 111 1 1 1
Z-A27  EIVLTQSPGTLSLSPGERATLSC RASQSVSSSYLA     WYQQKPGQAPRLLIY GASSRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQYGSSP
       ↑ ^                   ↑  ↑    ↑Δ      Δ Δ    ΔΔ Δ^↑Δ      Δ   ^   ^ ↑      ↑              Δ  Δ↑Δ  Δ↑
```

VLK IV

```
            10        20        30            40        50        60        70        80        90
12G8   DIQMTQSPSLLSASVGDRVTLNC KTSQNIF------ENLA WYQQKLREPPKLLIF NASPLQA GIPSRFSGSGSGTDFTLTITSLQPEDVATYFC HQYYSGY
47      4 3                            42  2 2     22 234             3 4     4                  42
39     1   1111  1  1 1 1 1 11              1 1 1     1           1 1 1 1 111111 1111 111 1111 1 1
Z-B3   DIVMTQSPDSLAVSLGERATINC KSSQSVLYSSNNKNYLA WYQQKPGQPPKLLIY WASTRES GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQYYSTP
       ↑ ^                   ↑  ↑       ↑Δ  Δ Δ    ΔΔ Δ^↑Δ      Δ   ^   ^ ↑      ↑              Δ  Δ↑Δ  Δ↑
```

(57) Abstract: The methods and compositions provided herein relate generally to IL-10 specific antibodies and uses thereof. More specifically, compositions of humanized IL-10 specific antibodies and methods to use such antibodies in modulating the biological activity of IL-10, particularly in autoimmune disorders and pathogen-mediated immunopathology.

WO 2005/047326 A2

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.